Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG-fluorescence Imaging for Breast Cancer Margins
NCT06227338Recruiting
- Sponsor
- Institut Jules Bordet
- Start
- Feb 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of indocyanine green in breast cancer (5 arms), sponsored by Institut Jules Bordet. Primary endpoint: Accuracy of ICG-FI technique for the detection of positive (involved) surgical margins at the patient level at 2 years. Started Feb 2024; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06227338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06227338.